Press News

Press News

2013.07.17 Development of New Immunotherapy for Autoimmune Diseases and Allergies by Using a New Technology That Utilizes the Effects of Dendritic Cells (DC)~tella receives exclusive right for use of technology concerning regulatory DC~

tella, Inc. (Head office: Chiyoda-ku, Tokyo; President & Representative Director: Yuichiro Yazaki, hereinafter “the Company”) has received an exclusive utilization right*1 concerning the adjustment method for regulatory DC and applications (patent 4547174). As a result, tella can proceed with the development of a new immunotherapy for individuals with autoimmune diseases and allergies in addition to continuing work on the DC vaccine therapy*2 for the treatment of cancer. DCs regulate the immune system and transfer the characteristics of foreign substances to immune cells. These cells attack microbes and viruses as well as cancer cells by enveloping them and activating lymphocytes.
There are also DCs called immune tolerance DC that prevent the excessive activation of the immune system. Using the properties of these immune tolerance cells may have clinical applications for the treatment of autoimmune diseases (rheumatoid arthritis, multiple sclerosis, ulcerative colitis, Crohn’s disease, etc.) and allergies (asthma, pollen and food allergies, atopic eczema, etc.), where the body attacks its own cells or harmless foreign substances (pollen, foods, etc.) Autoimmune diseases and allergies are inflammations caused when lymphocytes attack the body’s own cells or harmless foreign substances. One potential treatment is to suppress the activation of T-cells (one type of lymphocyte), which are the cause of the inflammation. However, a method was needed to improve immune tolerance DC because of the weak ability of these cells to suppress T-cell activation in clinical applications. To solve this problem, Professor Katsuaki Sato of the Faculty of Medicine at the University of Miyazaki developed regulatory DC. Compared with ordinary immune tolerance DC, the regulatory DC can significantly hold down T-cell immunity activation. Furthermore, these cells are very effective at attracting T-cells that suppress immunity. As a result, it is possible to maintain an even more powerful suppression of immunity in an inflammatory environment.

The Company is performing research and development activities involving the DC vaccine therapy and other therapies for cancer. In addition, the Company is studying clinical applications for this new technology and will work on developing new immunotherapies to treat autoimmune diseases and allergies.

This matter will have only a negligible effect on results of operations in fiscal 2013.